Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461430 · ClinicalTrials.gov registry record
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
A clinical trial of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell, sponsored by Travera.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05461430: Recruiting study of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell, sponsored by Travera.
NCT05461430 is a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell that is actively recruiting participants, run by Travera. The registered enrollment target is 200 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05461430, a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Travera.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Primary Outcome
Best overall response
Conditions Studied
Study Locations (1)
California
- xCures - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2028-07 |
What NCT05461430 shows while recruiting
NCT05461430 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (38% lower).
The record links to 10 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.
NCT05461430 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05461430 about?
NCT05461430 is a clinical study titled "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)". The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malig...
What is the current status of trial NCT05461430?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-07-15. Estimated completion is 2028-07.
What conditions does trial NCT05461430 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Carcinoma, Renal Cell, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Pancreatic Ductal.
Who is sponsoring clinical trial NCT05461430?
This trial is sponsored by Travera, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05461430 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05461430's enrollment target sits among peer trials
200 50th of 130 higher than 81 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI